Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015.

Tang W, Xie J, Kong F, Malone DC.

Value Health. 2019 Aug;22(8):871-877. doi: 10.1016/j.jval.2019.03.004. Epub 2019 May 17.

PMID:
31426927
2.

Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study.

Bhattacharjee S, Patanwala AE, Lo-Ciganic WH, Malone DC, Lee JK, Knapp SM, Warholak T, Burke WJ.

Alzheimers Dement (N Y). 2019 Jul 10;5:294-302. doi: 10.1016/j.trci.2019.05.005. eCollection 2019.

3.

Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.

Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, Feltner DE, Dabbous O.

J Mark Access Health Policy. 2019 May 8;7(1):1601484. doi: 10.1080/20016689.2019.1601484. eCollection 2019.

4.

Clinician preferences for computerised clinical decision support for medications in primary care: a focus group study.

Trinkley KE, Blakeslee WW, Matlock DD, Kao DP, Van Matre AG, Harrison R, Larson CL, Kostman N, Nelson JA, Lin CT, Malone DC.

BMJ Health Care Inform. 2019 Apr;26(1):0. doi: 10.1136/bmjhci-2019-000015.

5.

Extent and Predictors of Potentially Inappropriate Antidepressant Use Among Older Adults With Dementia and Major Depressive Disorder.

Bhattacharjee S, Lee JK, Patanwala AE, Vadiei N, Malone DC, Knapp SM, Lo-Ciganic WH, Burke WJ.

Am J Geriatr Psychiatry. 2019 Aug;27(8):794-805. doi: 10.1016/j.jagp.2019.02.002. Epub 2019 Feb 7.

PMID:
30926273
6.

Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions.

Lo-Ciganic WH, Huang JL, Zhang HH, Weiss JC, Wu Y, Kwoh CK, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kuza CC, Gellad WF.

JAMA Netw Open. 2019 Mar 1;2(3):e190968. doi: 10.1001/jamanetworkopen.2019.0968.

7.

Biosimilars: Considerations for Payers.

Smeeding J, Malone DC, Ramchandani M, Stolshek B, Green L, Schneider P.

P T. 2019 Jan;44(2):54-63.

8.

Identifying Common Methods Used by Drug Interaction Experts for Finding Evidence About Potential Drug-Drug Interactions: Web-Based Survey.

Grizzle AJ, Horn J, Collins C, Schneider J, Malone DC, Stottlemyer B, Boyce RD.

J Med Internet Res. 2019 Jan 4;21(1):e11182. doi: 10.2196/11182.

9.

Warnings for drug-drug interactions in consumer medication information provided by community pharmacies.

Panich J, Gooden A, Shirazi FM, Malone DC.

J Am Pharm Assoc (2003). 2019 Jan - Feb;59(1):35-42. doi: 10.1016/j.japh.2018.09.008. Epub 2018 Nov 8.

PMID:
30416068
10.

Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dirven L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Sloan J, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium (SISAQOL).

Lancet Oncol. 2018 Sep;19(9):e459-e469. doi: 10.1016/S1470-2045(18)30418-2.

11.

Assessing the incidence of acidosis in patients receiving metformin with and without risk factors for lactic acidosis.

Trinkley KE, Anderson HD, Nair KV, Malone DC, Saseen JJ.

Ther Adv Chronic Dis. 2018 Jun 13;9(9):179-190. doi: 10.1177/2040622318779760. eCollection 2018 Sep.

12.

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.

Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro JZ, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Sridhara R, Taphoorn MJB, Velikova G, Coens C.

Clin Trials. 2018 Dec;15(6):624-630. doi: 10.1177/1740774518795637. Epub 2018 Aug 24.

13.

Sensory Overload and Technology in Critical Care.

Wung SF, Malone DC, Szalacha L.

Crit Care Nurs Clin North Am. 2018 Jun;30(2):179-190. doi: 10.1016/j.cnc.2018.02.001. Epub 2018 Mar 20.

PMID:
29724437
14.
15.

Are US Health Insurers Efficient or Not?

Malone DC.

Value Health. 2018 Apr;21(4):398-399. doi: 10.1016/j.jval.2017.12.020. Epub 2018 Mar 7. No abstract available.

16.

Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?

Malone DC, Brown M, Hurwitz JT, Peters L, Graff JS.

Value Health. 2018 Mar;21(3):326-333. doi: 10.1016/j.jval.2017.08.3013. Epub 2017 Oct 18.

17.

Economic impact of epilepsy and the cost of nonadherence to antiepileptic drugs in older Medicare beneficiaries.

Ip Q, Malone DC, Chong J, Harris RB, Labiner DM.

Epilepsy Behav. 2018 Mar;80:208-214. doi: 10.1016/j.yebeh.2018.01.009. Epub 2018 Feb 3.

PMID:
29414554
18.

An update on the prevalence and incidence of epilepsy among older adults.

Ip Q, Malone DC, Chong J, Harris RB, Labiner DM.

Epilepsy Res. 2018 Jan;139:107-112. doi: 10.1016/j.eplepsyres.2017.11.022. Epub 2017 Dec 5.

PMID:
29220741
19.

An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.

Geskin L, Malone DC.

J Dermatolog Treat. 2018 Aug;29(5):522-530. doi: 10.1080/09546634.2017.1412064. Epub 2017 Dec 18.

PMID:
29191068
20.

Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?

Hurwitz JT, Brown M, Graff JS, Peters L, Malone DC.

J Manag Care Spec Pharm. 2017 Jun;23(6):613-620. doi: 10.18553/jmcp.2017.16368. Epub 2017 Mar 16.

21.

Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial.

Siaw MYL, Ko Y, Malone DC, Tsou KYK, Lew YJ, Foo D, Tan E, Chan SC, Chia A, Sinaram SS, Goh KC, Lee JY.

J Clin Pharm Ther. 2017 Aug;42(4):475-482. doi: 10.1111/jcpt.12536. Epub 2017 Apr 27.

PMID:
28449205
22.

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.

Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro J, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Coens C; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium.

Lancet Oncol. 2016 Nov;17(11):e510-e514. doi: 10.1016/S1470-2045(16)30510-1. Epub 2016 Oct 18. Review.

23.

Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available.

Samwald M, Xu H, Blagec K, Empey PE, Malone DC, Ahmed SM, Ryan P, Hofer S, Boyce RD.

PLoS One. 2016 Oct 20;11(10):e0164972. doi: 10.1371/journal.pone.0164972. eCollection 2016.

24.

Prescribing attitudes, behaviors and opinions regarding metformin for patients with diabetes: a focus group study.

Trinkley KE, Malone DC, Nelson JA, Saseen JJ.

Ther Adv Chronic Dis. 2016 Sep;7(5):220-8. doi: 10.1177/2040622316657328. Epub 2016 Aug 11.

25.

International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework.

Malone DC, Berg NS, Claxton K, Garrison LP Jr, IJzerman M, Marsh K, Neumann PJ, Sculpher M, Towse A, Uyl-de Groot C, Weinstein MC.

J Clin Oncol. 2016 Aug 20;34(24):2936-7. doi: 10.1200/JCO.2015.64.4328. Epub 2016 Jun 13. No abstract available.

26.

The economic burden of spinal muscular atrophy.

Armstrong EP, Malone DC, Yeh WS, Dahl GJ, Lee RL, Sicignano N.

J Med Econ. 2016 Aug;19(8):822-6. doi: 10.1080/13696998.2016.1198355. Epub 2016 Jun 13.

PMID:
27264163
27.

Ability and Use of Comparative Effectiveness Research by P&T Committee Members and Support Staff: A 1-Year Follow-up.

Augustine J, Warholak TL, Hines LE, Sun D, Brown M, Hurwitz J, Taylor AM, Brixner D, Cobaugh DJ, Schlaifer M, Malone DC.

J Manag Care Spec Pharm. 2016 Jun;22(6):618-25. doi: 10.18553/jmcp.2016.22.6.618.

28.

Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma.

Schultz NM, Wong WB, Coleman AL, Malone DC.

Am J Ophthalmol. 2016 Aug;168:78-85. doi: 10.1016/j.ajo.2016.05.001. Epub 2016 May 10.

PMID:
27173373
29.

Recommendations for selecting drug-drug interactions for clinical decision support.

Tilson H, Hines LE, McEvoy G, Weinstein DM, Hansten PD, Matuszewski K, le Comte M, Higby-Baker S, Hanlon JT, Pezzullo L, Vieson K, Helwig AL, Huang SM, Perre A, Bates DW, Poikonen J, Wittie MA, Grizzle AJ, Brown M, Malone DC.

Am J Health Syst Pharm. 2016 Apr 15;73(8):576-85. doi: 10.2146/ajhp150565.

30.

Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics.

Yehoshua A, Chancellor M, Vasavada S, Malone DC, Armstrong EP, Joshi M, Campbell K, Pulicharam R.

J Manag Care Spec Pharm. 2016 Apr;22(4):406-13. doi: 10.18553/jmcp.2016.22.4.406.

31.

Relationship Between Patients' Perceptions of Care Quality and Health Care Errors in 11 Countries: A Secondary Data Analysis.

Hincapie AL, Slack M, Malone DC, MacKinnon NJ, Warholak TL.

Qual Manag Health Care. 2016 Jan-Mar;25(1):13-21. doi: 10.1097/QMH.0000000000000079.

32.

Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.

McGarry LJ, Chen YJ, Divino V, Pokras S, Taylor CR, Munakata J, Nieset CC, Huang H, Jabbour E, Malone DC.

Curr Med Res Opin. 2016;32(2):289-99. doi: 10.1185/03007995.2015.1120189. Epub 2015 Nov 30.

PMID:
26566171
33.

Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.

Park H, Rascati KL, Lawson KA, Barner JC, Richards KM, Malone DC.

J Manag Care Spec Pharm. 2015 Oct;21(10):956-64.

34.

Antidepressant use and risk of recurrent stroke: a population-based nested case-control study.

Wang MT, Chu CL, Yeh CB, Chang LC, Malone DC, Liou JT.

J Clin Psychiatry. 2015 Jul;76(7):e877-85. doi: 10.4088/JCP.14m09134.

PMID:
26231015
35.

Effect of adjustable gastric banding on quality of life and weight loss in the Helping Evaluate Reduction in Obesity (HERO) registry study: 2 year analysis.

Lao WL, Malone DC, Armstrong EP, Voellinger D, Somers S, Jin J, Dreyer N, Globe D.

Curr Med Res Opin. 2015 Aug;31(8):1451-60. doi: 10.1185/03007995.2015.1059802. Epub 2015 Jul 25.

PMID:
26154653
36.

Prevalence and Incidence of Epilepsy in an Elderly and Low-Income Population in the United States.

Tang DH, Malone DC, Warholak TL, Chong J, Armstrong EP, Slack MK, Hsu CH, Labiner DM.

J Clin Neurol. 2015 Jul;11(3):252-61. doi: 10.3988/jcn.2015.11.3.252. Epub 2015 May 28.

37.

Recommendations to improve the usability of drug-drug interaction clinical decision support alerts.

Payne TH, Hines LE, Chan RC, Hartman S, Kapusnik-Uner J, Russ AL, Chaffee BW, Hartman C, Tamis V, Galbreth B, Glassman PA, Phansalkar S, van der Sijs H, Gephart SM, Mann G, Strasberg HR, Grizzle AJ, Brown M, Kuperman GJ, Steiner C, Sullins A, Ryan H, Wittie MA, Malone DC.

J Am Med Inform Assoc. 2015 Nov;22(6):1243-50. doi: 10.1093/jamia/ocv011. Epub 2015 Mar 30. Review.

PMID:
25829460
38.

Lower urinary tract symptom prevalence and management among patients with multiple sclerosis.

Khalaf KM, Coyne KS, Globe DR, Armstrong EP, Malone DC, Burks J.

Int J MS Care. 2015 Jan-Feb;17(1):14-25. doi: 10.7224/1537-2073.2013-040.

39.

Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support.

Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, Abernethy DR, Horn JR, Sklar SJ, Wong SK, Jones G, Brown ML, Grizzle AJ, Comes S, Wilkins TL, Borst C, Wittie MA, Malone DC.

Drug Saf. 2015 Feb;38(2):197-206. doi: 10.1007/s40264-014-0262-8.

40.

Economic Evaluation of Paclitaxel Albumin, Paclitaxel, and Docetaxel as a Second Line Treatment for Metastatic Breast Cancer.

Gharaibeh M, Malone DC.

Value Health. 2014 Nov;17(7):A640. doi: 10.1016/j.jval.2014.08.2305. Epub 2014 Oct 26. No abstract available.

41.

The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis.

Khalaf KM, Coyne KS, Globe DR, Malone DC, Armstrong EP, Patel V, Burks J.

Neurourol Urodyn. 2016 Jan;35(1):48-54. doi: 10.1002/nau.22670. Epub 2014 Oct 18.

42.

Costs and utilization of hemophilia A and B patients with and without inhibitors.

Armstrong EP, Malone DC, Krishnan S, Wessler MJ.

J Med Econ. 2014 Nov;17(11):798-802. doi: 10.3111/13696998.2014.953679. Epub 2014 Aug 20.

PMID:
25111634
43.

Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.

Park H, Rascati KL, Lawson KA, Barner JC, Richards KM, Malone DC.

J Manag Care Spec Pharm. 2014 Aug;20(8):862-76.

44.

Adherence to clotting factors among persons with hemophilia A or B.

Armstrong EP, Malone DC, Krishnan S, Wessler MJ.

Hematology. 2015 Apr;20(3):148-53. doi: 10.1179/1607845414Y.0000000176. Epub 2014 Jul 7.

PMID:
25001343
45.

Evaluation of an educational program on deciphering heterogeneity for medical coverage decisions.

Warholak TL, Hilgaertner JW, Dean JL, Taylor AM, Hines LE, Hurwitz J, Brown M, Malone DC.

J Manag Care Spec Pharm. 2014 Jun;20(6):566-73.

46.

The good, the bad, and the different: a primer on aspects of heterogeneity of treatment effects.

Malone DC, Hines LE, Graff JS.

J Manag Care Spec Pharm. 2014 Jun;20(6):555-63.

47.

Prescriber perceptions of a near real-time fax alert program for potential drug-drug interactions.

Armstrong EP, Wang SM, Hines LE, Patel BV, Leslie RS, Malone DC.

J Manag Care Spec Pharm. 2014 May;20(5):494-500a.

48.

Evaluation of Pharmacy and Therapeutic (P&T) Committee member knowledge, attitudes and ability regarding the use of comparative effectiveness research (CER) in health care decision-making.

Tang DH, Warholak TL, Hines LE, Hurwitz J, Brown M, Taylor AM, Brixner D, Malone DC.

Res Social Adm Pharm. 2014 Sep-Oct;10(5):768-80. doi: 10.1016/j.sapharm.2013.11.008. Epub 2013 Dec 3.

PMID:
24480384
49.

Health care decision makers' use of comparative effectiveness research: report from a series of focus groups.

Villa L, Warholak TL, Hines LE, Taylor AM, Brown M, Hurwitz J, Brixner D, Malone DC.

J Manag Care Pharm. 2013 Nov-Dec;19(9):745-54.

50.

Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis.

Villa LA, Malone DC, Ross D.

Int J Hematol. 2013 Oct;98(4):390-7. doi: 10.1007/s12185-013-1445-2. Epub 2013 Sep 21.

PMID:
24057162

Supplemental Content

Loading ...
Support Center